The results imply that the ability of mutant KRAS to modulate tumor immunity (via involvement of the RAF, PI3K, and MYC pathways) is an essential component of its oncogenicity, and that treatment of cancer will be improved by different modalities acting to simultaneously inhibit KRAS and activate immune pathways suppressed by cancer. This evidence concerns the gene PIK3CA and neoplasm.